medigraphic.com
ISSN 1817-5996 (Electronic)

2020, Number 3

Next >>

Rev Cub de Reu 2020; 22 (3)

Strategies in its Management and Updating of the Autoimmune-rheumatic Diseases in the SARSCoV-2 Pandemic and COVID-19 Cuban Rheumatology Society and its National Group

Reyes LGA, Guibert TM, Hernández MA, Otero GZA, Bicet DE, Torres CR, Martínez LJP

Language: Spanish
References: 54
Page: 1-28
PDF size: 530.05 Kb.


ABSTRACT

The outbreak of the infection by the new coronavirus SARSCoV-2, COVID-19, in December in Wuhan Province of China, has become a pandemic and health emergency given the deficiency of antiviral therapy for the acute respiratory syndrome that generates danger to life. The debut of the epidemic was in China, then the epicenter developed in Europe, northern Italy that suffered a severe blow. Worldwide, more than 10 million people are infected with the virus that has impacted on health systems until it practically collapsed, resulting in thousands of deaths. Today the epicenter of the pandemic has shifted to the Americas. Alarming figures highlight the United States of North America with some 2,737,600 infected and more than 128,471 deaths, followed by the South American giant Brazil with 1.3 million infections and 57,659 deaths. The Caribbean has a better setting. In Cuba, by the end of June, 2,340 cases of patients infected with deaths from COVID-19 were reported. We conducted a review, analysis and evaluation study of more than 150 articles from international journals, update bulletins of the WEB sites, health pages of the MINSAP of Cuba, and summaries selected for their methodological quality, and reviews, on the subject COVID-19 and autoimmune-rheumatic diseases by MEDLINE: database prepared by the National Library of Medicine of The USA contains bibliographic references and abstracts from more than 4,000 biomedical journals published in the United States and in 70 other countries, We also use Latin American and Caribbean Center for Information on Health Sciences: System, in Latin America and the Caribbean, since 1982. Our objective and results achieved have been to develop the theoretical-practical bases in an updated scientific document that allow access in an essential and summarized way to current knowledge about the infection by SACOV-2, COVID-19, and its repercussion and impact on patients suffering from rheumatic autoimmune diseases, and thus outline a coping and action strategy with recommendations for the Cuban rheumatologists in their health care work, and for patients as a guideline, given their well-founded concerns and fears given their underlying condition and the immunosuppressive drugs prescribed in an unfavorable context of a pandemic. The information is based on international experiences with the most published scientific evidence and those treasured national experiences in the face of similar situations of epidemics, faced by the vast health system and achievements of Cuban science.


REFERENCES

  1. Askanase AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. Lupus Science & Medicine. 2020 [Acceso 12/01/2020];7(1):e000396. Disponible en: https://lupus.bmj.com/content/7/1/e000396.abstract

  2. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev. 2020 May [Acceso 12/01/2020];19(5):102523. Disponible: https://reader.elsevier.com/reader/sd/pii/S1568997220300781?token=CD44D6FF7269708A00B8208CD006C8013084BF400CCB97CE7B1CCA881F0A93C7A271A5329F59151C7467F710240D9F9D

  3. Ministerio de Salud Pública. Boletín informativo sobre la COVID-19. La Habana: Ministerio de Salud Pública de Cuba. Junio 2020. Disponible en: https://salud.msp.gob.cu/2020/06/

  4. Jara LJ, Medina G, Saavedra MA. Autoimmune manifestations of infections. Current Opinion in Rheumatology. 2018 Jul [Acceso 14/03/2020];30(4):373-37. Disponible en: https://journals.lww.com/co-rheumatology/Abstract/2018/07000/Autoimmune_manifestations_of_infections.13.aspx

  5. Waldmann H. Mechanisms of immunological tolerance. Clin Biochem. 2016 [Acceso 12/01/2020];49(4-5):324-8. Disponible en: https://www.sciencedirect.com/science/article/pii/S0009912015002106

  6. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May [Acceso 23/06/2020];109:102-433. Disponible en: https://www.sciencedirect.com/science/article/pii/S0896841120300469

  7. Little P, Read RC, Amlot R, Chadborn T, Rice C, Bostock J, et al. Reducing risks from coronavirus transmission in the home -the role of viral load. BMJ. 2020 [Acceso 20/06/2020];369:m1728. Disponible en: https://www.bmj.com/content/369/bmj.m1728.abstract

  8. Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning: Autoimmun Rev. 2020 Apr 5 [Acceso 20/06/2020];19(6):102538. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131471/

  9. Baden LR, Rubin EJ. Covid-19 -the search for effective therapy. N Engl J Med. 2020 Mar 18 [Acceso 21/05/2020];382:1851-2. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMe2005477

  10. Krause I, Wu R, Sherer Y, Patanik M, Peter J, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations -A potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med. 2002 [Acceso 12/01/2020];12:133-9. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-3148.2002.00360.x

  11. Amador-Patarroyo MJ, Rodriguez-Rodriguez A, Montoya-Ortiz G. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis. 2012 [Acceso 12/01/2020];2012:251730. Disponible en: http://downloads.hindawi.com/journals/ad/2012/251730.pdf

  12. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self-tolerance and autoimmunity. Nature. 2005 [Acceso 14/03/2020]; 435(7042):590-7. Disponible en: https://www.nature.com/articles/nature03724

  13. Zouali M. Immunological Tolerance: Mechanisms. In: eLS. John Wiley & Sons, Ltd: Chichester; 2014. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/9780470015902.a0000950.pub3

  14. Monsalve DM, Pacheco Y, Acosta-Ampudia Y. Zika virus and autoimmunity. One-step forward. Autoimmun Rev. 2017 [Acceso 14/03/2020];16(12):1237-45. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1568997217302586

  15. Jardim DL, Tsukumo DM, Angerami RN, de Carvhallo Filho MA, Saad MJA. Autoimmune features caused by dengue fever: a case report. Braz J Infect Dis. 2012 [Acceso 14/03/2020];16(1):92-5. Disponible en: https://www.sciencedirect.com/science/article/pii/S1413867012702830

  16. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004; [Acceso 14/03/2020];4(10):757-68. Disponible en: https://www.nature.com/articles/nrc1452

  17. Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis. 2006 [Acceso 26/04/2020];65(11):1500-05. Disponible en: https://ard.bmj.com/content/65/11/1500.short

  18. Quintero OL, Rojas-Villarraga A, Mantilla RD, Anaya JM. Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev. 2013 [Acceso 14/03/2020];12(3):380-95. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S156899721200119X

  19. Reyes Llerena GA, Guibert Toledano M, Hernández Martínez A, Millán JC. Patrón epidemiológico clínico de las espondiloartropatías seronegativas en una cohorte VIH-SIDA. Rev Colomb Reumatolog. 1997 [Acceso 12/01/2020];4(4):164-8.

  20. Reyes Llerena GA, Guibert Toledano M, Millán JC. Manifestaciones reumáticas en la epidemia VIH/SIDA en la era previa a la terapia antirretroviral sumamente activa en Cuba. Una puesta al día. Rev Peruana Reumatolog. 2016;22(3):25-33.

  21. Reyes Llerena GA, Guibert Toledano M, Torres Figueroa A, Navarro Camero A, Torres Carballeira R, Mirta Miranda Ley. Enfermedades reumáticas y complicaciones metabólicas en pacientes con VIH-SIDA con tratamiento antirretroviral de alta eficiencia. Rev Cubana Reumatol. 2018 [Acceso 14/03/2020];20(3):e33. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962018000300005&lng=es

  22. Reyes Llerena GA, Guibert Toledano ZM, Torres Figueroa A, Navarro Camero A, Garcés Martínez M, Sanchoyerto López R, et al. Lupus eritematosos sistémico en la epidemia VIH/SIDA. Reporte inicial de casos en Cuba. Rev Cubana Reumatol. 2019 [Acceso 22/03/2020];21(S1):1-14. Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/742/html_1

  23. Liao HY, Tao CM, Su J. Concomitant systemic lupus erythematosus and HIV infection: a rare case report and literature review. Medicine. 2017 [Acceso 14/03/2020];96(51):e9337. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758215/pdf/medi-96-e9337.pdf

  24. So H, Mok CC. COVID-19 and Rheumatic Diseases: Practical Issues. J Clinical Rheumatology Immunology. 2020 [Acceso 23/06/2020];2(1):21-4. Disponible en: https://www.worldscientific.com/doi/pdf/10.1142/S2661341720300025

  25. World Health Organization. Coronavirus disease 2019 (COVID-19) situation reports; 2020. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

  26. Joo YB, Lim YH, Kim KJ, Park KS, Park YJ. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res Ther. 2019 [Acceso 14/03/2020];21(1):199. Disponible en: https://link.springer.com/article/10.1186/s13075-019-1977-9.

  27. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013 [Acceso 12/01/2020];52(1):53-61. Disponible en: https://academic.oup.com/rheumatology/article/52/1/53/1830871

  28. Arleevskaya MI, Shafigullina AZ, Filina YV, Lemerle J, Renaudineau Y. Associations between viral infection history symptoms, granulocyte reactive oxygen species activity, and active rheumatoid arthritis disease in untreated women at onset: results from a longitudinal cohort study of Tatarstan women. Front Immunol. 2017 [Acceso 12/01/2020];8:1725. Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2017.01725/full

  29. De Thurah A, Stengaard-Pedersen K, Axelsen M, Fredberg U, Schougaard LMV, Hjollund NH, et al. Tele-health followup strategy for tight control of disease activity in rheumatoid arthritis: results of a randomized controlled trial. Arthritis Care Res. 2018 [Acceso 14/03/2020];70:353-60. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/acr.23280

  30. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 [Acceso 14/03/2020];46(9):2287-93. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/art.10524

  31. Australian Government Department of Health. Advice for people at risk of coronavirus (COVID-19); 2020. Disponible en: https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-

  32. McDougall JA, Ferucci ED, Glover J, Fraenkel L. Telerheumatology: a systematic review. Arthritis Care Res. 2017 [Acceso 12/01/2020];69(10):1546-57. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/acr.23153

  33. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 [Acceso 07/06/2020];368:m1091. Disponible en: https://www.bmj.com/content/368/bmj.m1091

  34. Swiss Federal Office of Public Health. New coronavirus: documents for health professionals. Disponible en: https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/information-fuerdie-aerzteschaft/dokumente-fuer-gesundheitsfachpersonen html

  35. Wang J, Liao Y, Wang X, Li Y, Jiang D, He J, et al. Incidence of novel coronavirus (2019-nCoV) infection among people under home quarantine in Shenzhen, China. Travel Medicine Infectious Disease. 2020 [Acceso 20/05/2020];101660. Disponible en: https://www.sciencedirect.com/science/article/pii/S1477893920301289

  36. Kuo CF, Chou IJ, Rees F, Grainge MJ, Lanyon P, Davenport G, et al. Temporal relationships between systemic lupus erythematosus and comorbidities. Rheumatology. 2019 [Acceso 12/01/2020];58(5):840-8. Disponible en: https://academic.oup.com/rheumatology/article-abstract/58/5/840/5253846

  37. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2013 [Acceso 14/03/2020];73(1):62-8. Disponible en: https://ard.bmj.com/content/annrheumdis/73/1/62.full.pdf

  38. Rodríguez PC, Torres-Moya R, Reyes G, Molinero C, Prada DM, López AM, et al. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results in Immunology. 2012 [Acceso 12/01/2020];2:204-11. Disponible en: https://www.sciencedirect.com/science/article/pii/S2211283912000263

  39. Montero E, Reyes GA, Guiber Toledano M, Torres O, Rodriguez N, Estrada J, et al. Immunodiagnosis and therapeutic immunosuppression in rheumatoid arthritis with ior t1 (anti-CD6) monoclonal antibody. Arthritis Res Ther. 2002 [Acceso 14/03/2020];4(1):1-38. Disponible en: https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar450

  40. Qiu CC, Caricchio R, Gallucci S. Triggers of autoimmunity: the role of bacterial infections in the extracellular exposure of lupus nuclear autoantigens. Front Immunol. 2019 [Acceso 14/03/2020];10:2608. Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02608/full

  41. Conigliaro P, Triggianese P, Ballanti E, Perricone C, Perricone R, Chimenti MS. Complement, infection and autoimmunity. Curr Opin Rheumatol. 2019 [Acceso 12/01/2020];31(5):532-41. Disponible en: https://journals.lww.com/co-rheumatology/Abstract/2019/09000/Complement,_infection,_and_autoimmunity.19.aspx

  42. Sawalha AH, Manzi S. Coronavirus Disease-2019: implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol. 2020 [Acceso 11/06/2020]. Disponible en: https://sle.dk/wp-content/uploads/2020/04/Corona-Lupus-11.04.2020-BD.pdf

  43. EULAR guidance for patients COVID-19 Outnreak. Update 17 March 2020. EULAR Task Force [Acceso 02/05/2020]. Disponible en: https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm

  44. Cai K, He J, Wong PK, Manolios N. The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia. Eur J Rheumatol. 2020 [Acceso 02/05/2020]. Disponible en: https://eurjrheumatol.org/Content/files/sayilar/195/20060.pdf

  45. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals Rheum Dis. 2020 [Acceso 09/05/2020];79(5):667-8. Disponible en: https://ard.bmj.com/content/79/5/667.full

  46. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF. Rheumatic disease and COVID-19: initial data from the COVID-19. Global Rheumatology Alliance provider registries. The Lancet. 2020 [Acceso 22/05/2020];2(5):e250-3. Disponible en: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30095-3/fulltext

  47. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2020 [Acceso 24/05/2020];Epub. Disponible en: https://ard.bmj.com/content/annrheumdis/early/2020/04/22/annrheumdis-2020-217615.full.pdf

  48. Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther. 2018 [Acceso 14/03/2020];16(10):781-91. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/14787210.2018.1521270

  49. D'Antiga L. Coronaviruses and immunosuppressed patients: The facts during the third epidemic. Liver Transpl. 2020 [Acceso 24/05/2020];26(6):832-4. Disponible en: https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.25756

  50. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 [Acceso 24/05/2020];27:1451-4. Disponible en: https://www.nature.com/articles/s41418-020-0530-3?fbclid=IwAR2ZxeCwG6GQEZTC1GQbizfu0d5i1wqIREmK5IKRgeR2TsUc1dg8ta1GYyA

  51. Milkus TR, Johnson SR, Fraenke L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology. Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis & Rheumatology. 2020 [Acceso 11/06/2020];72(8):1241-51. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/art.41301

  52. O'Dell JR. Treatment of rheumatoid arthritis. In: Kelley and Firestein's Textbook of Rheumatology. Barcelona: Elsevier; 2017. p. 1187-212.

  53. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Quintana R, Gómez-Puerta JA, Catoggio LJ, et al. Predictors of remission and low disease activity state in systemic lupus erythematosus: Data from a multiethnic, multinational Latin American cohort. J Rheumatol. 2019 [Acceso 14/03/2020];46(10):1299-1308. Disponible en: https://www.jrheum.org/content/46/10/1299.abstract

  54. Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018 [Acceso 14/03/2020];77(11):1549-57. Disponible en: https://ard.bmj.com/content/77/11/1549?etoc=&int_source=trendmd&int_medium=trendmd&int_campaign=trendmd




2020     |     www.medigraphic.com